H. Lorenz, M. Grunke, J. Wendler
Sep 14, 2005
Citations
0
Influential Citations
13
Citations
Journal
Annals of the Rheumatic Diseases
Abstract
Optimal treatment for patients with relapsing lupus nephritis remains unclear. The ability of 15-deoxyspergualin (gusperimus; 15-DSG) to suppress systemic lupus erythematosus (SLE)-like diseases has been demonstrated in animals and humans.1–4 15-DSG exerted no nephrotoxicity or hepatotoxicity but reversibly induced leucocytopenia.5,6 In this study we aimed at evaluating the safety of 15-DSG in the treatment of glomerulonephritis associated with SLE. Table 1 shows the patient characteristics. View this table: Table 1 Details of the patients’ history, especially previous immunosuppressive treatment, signs of SLE-GN activity or general SLE activity at entry, and indicators for response during/after 15-DSG treatment 15-DSG was provided by Nippon Kayaku Co Ltd, Tokyo, Japan. Patients gave their informed consent, and 15-DSG 0.5 mg/kg normal body weight (height in cm minus 100)/day was self administered subcutaneously for 14 days, followed by a break of 7 days ( = 1 cycle). The dose was adjusted (dependent on efficacy or safety, or both) after cycles 4 and 6 to 0.35 mg/kg and 0.25 mg/kg, or 0.7 mg/kg and 1.0 mg/kg. ### Patient 1 After a bolus, daily …